Purchase solidifies group’s goal of expanding patient access to rare disease treatments.
Chiesi Farmaceutici S.p.A., a research-focused biopharmaceuticals and healthcare group, has acquired Amryt Pharma Plc, a global, commercial-stage biopharmaceutical company that obtains, develops, and commercializes novel treatments for rare diseases.
“We are excited to add the Amryt family to our company in this acquisition that demonstrates our commitment to rare diseases and aligns with our growth strategy through partnerships beyond internal research and development,” says Giacomo Chiesi, head of Chiesi Global Rare Diseases. “Amryt has unique and clinically differentiated products and additional promising drugs in its pipeline, and, as a benefit corporation certified B Corp, Chiesi has a patient-centric and sustainable model in place to make these treatments available to even more patients who need them.”
